Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Consulting agrmnt
AKCEA THERAPEUTICS, INC. (AKCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Akcea Reports Financial Results and Highlights for Third Quarter 2019"
08/06/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2019 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, MA 02210 Registrant's Telephone Number, Including Area Code: 207-0202 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Akcea Reports Financial Results and Highlights for First Quarter 2019"
02/26/2019 8-K Quarterly results
11/05/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2018 Akcea Therapeutics, Inc. Delaware 001-38137 47-2608175 22 Boston Wharf Road 9th Floor Boston, Massachusetts 02210 Registrant's telephone number, including area code: 207-0202 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Akcea Reports Financial Results and Highlights for Third Quarter 2018"
08/06/2018 8-K Quarterly results
Docs: "Cambridge, Mass., August 6, 2018 -- Akcea Therapeutics, Inc. , an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases,"
05/03/2018 8-K Quarterly results
Docs: "Cambridge, Mass., May 3, 2018 -- Akcea Therapeutics, Inc. , an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2018. The company reported a net loss for the first quarter ended March 31, 2018 of $30 million on a GAAP basis and $23 million on a pro forma basis. Akcea had $245 million of cash, cash equivalents and short-term investments as of March 31, 2018. In April, Akcea received an additional $200 million of cash for the issuance of 10.7 million shares to Ionis, providing additional funds to launch two drugs in 2018 and advance the Company’s pipeline, including AKCEA-TTR-L Rx ."
02/27/2018 8-K Quarterly results
Docs: "Cambridge, Mass., February 26, 2018"
11/06/2017 8-K Quarterly results
Docs: "Cambridge, Mass., November 6, 2017"
08/08/2017 8-K Quarterly results
Docs: "Cambridge, Mass., August 8, 2017"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy